Axsome Therapeutics (AXSM) Gross Margin (2022 - 2025)
Historic Gross Margin for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to 93.03%.
- Axsome Therapeutics' Gross Margin rose 10900.0% to 93.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 91.86%, marking a year-over-year increase of 7800.0%. This contributed to the annual value of 91.37% for FY2024, which is 10000.0% up from last year.
- Per Axsome Therapeutics' latest filing, its Gross Margin stood at 93.03% for Q3 2025, which was up 10900.0% from 91.04% recorded in Q2 2025.
- Over the past 5 years, Axsome Therapeutics' Gross Margin peaked at 93.03% during Q3 2025, and registered a low of 88.58% during Q3 2022.
- For the 4-year period, Axsome Therapeutics' Gross Margin averaged around 90.72%, with its median value being 90.9% (2025).
- As far as peak fluctuations go, Axsome Therapeutics' Gross Margin plummeted by -9100bps in 2023, and later skyrocketed by 32500bps in 2024.
- Axsome Therapeutics' Gross Margin (Quarter) stood at 90.6% in 2022, then dropped by -1bps to 89.69% in 2023, then increased by 2bps to 91.15% in 2024, then grew by 2bps to 93.03% in 2025.
- Its last three reported values are 93.03% in Q3 2025, 91.04% for Q2 2025, and 91.94% during Q1 2025.